Biomea Fusion is a clinical-stage biopharmaceutical company focused on discovering and developing oral, small molecule drugs for diabetes, obesity, and metabolic diseases. The company's lead program, icovamenib, is a selective menin inhibitor designed to restore beta cell function and enhance insulin secretion in type 1 and type 2 diabetes and obesity, while its second program, BMF-650, is a GLP-1 receptor agonist for obesity treatment. Biomea Fusion targets large patient populations with significant unmet medical needs—including severe insulin-deficient diabetics and GLP-1 non-responders—and plans to commercialize its drug candidates by building a focused sales organization in the United States and pursuing partnerships in other regions, retaining full development and commercialization rights to its programs.